## PATENT APPLICATION DECLARATION

(Attorney's Docket No.: 3100.002US1)

Each of the Applicants named below hereby declares as follows:

- 1. My residence, post office address and country of citizenship given below are true and correct.
- 2. I believe I am the original, first and joint inventor of the subject matter which is claimed and for which a patent is sought in the patent application entitled "ENDODERM, CARDIAC AND NEURAL INDUCING FACTORS," Serial No. 08/878,474, filed June 18, 1997, and I have reviewed and understand the contents of the specification, including its claims.
- 3. I acknowledge my duty to disclose to the Office all information known to me to be material to patentability of this application, in accordance with 37 C.F.R. Section 1.56, which is defined on the attached page.
- 4. This application claims the benefit of U.S. Provisional Application No. 60/020,150, filed June 20, 1996. I acknowledge my duty to disclose information of which I am aware which is material to the examination of this application, as defined in §1.56, which occurred between the filing date of the prior application and the filing date of this application.

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Date: 188 22, 1999

Co Ne Pyler Sedward M. De Robertis

Residence and

Residence and 16958 Dulce Ynez Lane

Post Office Address: Pacific Palisades, California 90272

(Citizenship: V.S.A.)

Date: 22 - 2 - 99

Texas Bouwmeester

Residence and Ploeck 86

Post Office Address: 69117 He

69117 Heidelberg, Germany

(Citizenship: The Netherlands)

## Section 1.56 Duty to Disclose Information Material to Patentability.

- A patent by its very nature is affected with a public interest. The public interest is best served, and the most effective patent examination occurs when, at the time an application is being examined, the Office is aware of and evaluates the teachings of all information material to patentability. Each individual associated with the filing and prosecution of a patent application has a duty of candor and good faith in dealing with the Office, which includes a duty to disclose to the Office all information known to that individual to be material to patentability as defined in this section. The duty to disclose information exists with respect to each pending claim until the claim is cancelled or withdrawn from consideration, or the application becomes abandoned. Information material to the patentability of a claim that is cancelled or withdrawn from consideration need not be submitted if the information is not material to the patentability of any claim remaining under consideration in the application. There is no duty to submit information which is not material to the patentability of any existing claim. The duty to disclose all information known to be material to patentability is deemed to be satisfied if all information known to be material to patentability of any claim issued in a patent was cited by the Office or submitted to the Office in the manner prescribed by §§ 1.97(b)-(d) and 1.98. However, no patent will be granted on an application in connection with which fraud on the Office was practiced or attempted or the duty of disclosure was violated through bad faith or intentional misconduct. The Office encourages applicants to carefully examine:
  - (1) prior art cited in search reports of a foreign patent office in a counterpart application, and
  - (2) the closest information over which individuals associated with the filing or prosecution of a patent application believe any pending claim patentably defines, to make sure that any material information contained therein is disclosed to the Office.
- (b) Under this section, information is material to patentability when it is not cumulative to information already of record or being made of record in the application, and
  - (1) It establishes, by itself or in combination with other information, a prima facie case of unpatentability of a claim, or
    - (2) It refutes, or is inconsistent with, a position the applicant takes in:
      - (i) Opposing an argument of unpatentability relied on by the Office, or
      - (ii) Asserting an argument of patentability.

A prima facie case of unpatentability is established when the information compels a conclusion that a claim is unpatentable under the preponderance of evidence, burden-of-proof standard, giving each term in the claim its broadest reasonable construction consistent with the specification, and before any consideration is given to evidence which may be submitted in an attempt to establish a contrary conclusion of patentability.

- (c) Individuals associated with the filing or prosecution of a patent application within the meaning of this section are:
  - (1) Each inventor named in the application;
  - (2) Each attorney or agent who prepares or prosecutes the application; and
  - (3) Every other person who is substantively involved in the preparation or prosecution of the application and who is associated with the inventor, with the assignce or with anyone to whom there is an obligation to assign the application.
- (d) Individuals other than the attorney, agent or inventor may comply with this section by disclosing information to the attorney, agent, or inventor.

#### PATENT APPLICATION DECLARATION

(Attorney's Docket No.: 3100.002US1)

Each of the Applicants named below hereby declares as follows:

- My residence, post office address and country of citizenship given below are true and correct.
- 2. I believe I am the original, first and joint inventor of the subject matter which is claimed and for which a patent is sought in the patent application entitled "ENDODERM, CARDIAC AND NEURAL INDUCING FACTORS," Serial No. 08/878,474, filed June 18, 1997, and I have reviewed and understand the contents of the specification, including its claims.
- I acknowledge my duty to disclose to the Office all information known 3. to me to be material to patentability of this application, in accordance with 37 C.F.R. Section 1.56, which is defined on the attached page.
- This application claims the benefit of U.S. Provisional Application No. 60/020,150, filed June 20, 1996. I acknowledge my duty to disclose information of which I am aware which is material to the examination of this application, as defined in §1.56, which occurred between the filing date of the prior application and the filing date of this application.

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Date: 8/31/98

Edward M. De Robertis

E. DeRobert

Residence and 16958 Dulce Ynez Lane

Post Office Address: Pacific Palisades, California 90272

(Citizenship: V.S.A.)

Date: 9/4/98

Residence and 827 Levering Avenue, Apt. #708 Post Office Address Los Angeles, California 90024

(Citizenship: The Netherlands)

\* new address: Tewis Bounneester

-1-

Serial No.: 08/878,474

PLOECK 56 69117 Heidelberg, GERMAN

#### Section 1.56 Duty to Disclose Information Material to Patentability.

- A patent by its very nature is affected with a public interest. The public interest (a) is best served, and the most effective patent examination occurs when, at the time an application is being examined, the Office is aware of and evaluates the teachings of all information material to patentability. Each individual associated with the filing and prosecution of a patent application has a duty of candor and good faith in dealing with the Office, which includes a duty to disclose to the Office all information known to that individual to be material to patentability as defined in this section. The duty to disclose information exists with respect to each pending claim until the claim is cancelled or withdrawn from consideration, or the application becomes abandoned. Information material to the patentability of a claim that is cancelled or withdrawn from consideration need not be submitted if the information is not material to the patentability of any claim remaining under consideration in the application. There is no duty to submit information which is not material to the patentability of any existing claim. The duty to disclose all information known to be material to patentability is deemed to be satisfied if all information known to be material to patentability of any claim issued in a patent was cited by the Office or submitted to the Office in the manner prescribed by §§ 1.97(b)-(d) and 1.98. However, no patent will be granted on an application in connection with which fraud on the Office was practiced or attempted or the duty of disclosure was violated through bad faith or intentional misconduct. The Office encourages applicants to carefully examine:
  - (1) prior art cited in search reports of a foreign patent office in a counterpart application, and
  - (2) the closest information over which individuals associated with the filing or prosecution of a patent application believe any pending claim patentably defines, to make sure that any material information contained therein is disclosed to the Office.
- (b) Under this section, information is material to patentability when it is not cumulative to information already of record or being made of record in the application, and
  - (1) It establishes, by itself or in combination with other information, a prima facie case of unpatentability of a claim; or
    - (2) It refutes, or is inconsistent with, a position the applicant takes in:
      - (i) Opposing an argument of unpatentability relied on by the Office, or
      - (ii) Asserting an argument of patentability.

A prima facie case of unpatentability is established when the information compels a conclusion that a claim is unpatentable under the preponderance of evidence, burden-of-proof standard, giving each term in the claim its broadest reasonable construction consistent with the specification, and before any consideration is given to evidence which may be submitted in an attempt to establish a contrary conclusion of patentability.

- (c) Individuals associated with the filing or prosecution of a patent application within the meaning of this section are:
  - (1) Each inventor named in the application;
  - (2) Each attorney or agent who prepares or prosecutes the application; and
  - (3) Every other person who is substantively involved in the preparation or prosecution of the application and who is associated with the inventor, with the assignee or with anyone to whom there is an obligation to assign the application.
- (d) Individuals other than the attorney, agent or inventor may comply with this section by disclosing information to the attorney, agent, or inventor.

# PATENT APPLICATION DECLARATION (Attorney's Docket No.: 3100.002US1) (UC Case No.: LA96-092-01)

Each of the Applicants named below hereby declares as follows:

- My residence, post office address and country of citizenship given below are true and correct.
- I believe I am the original, first and joint inventor of the subject matter which is claimed and for which a patent is sought in the patent application entitled "ENDODERM, CARDIAC AND NEURAL INDUCING FACTORS," Serial No. 08/878,474, filed June 18, 1997, and I have reviewed and understand the contents of the specification, including its claims.
- I acknowledge my duty to disclose to the Office all information known to me to be material to patentability of this application, in accordance with 37 C.F.R. Section 1.56, which is defined on the attached page.

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

09/18/97

Coll Roberts

Residence and Post Office Address: Edward M. De Robertis 16958 Dulce Ynez Lane Pacific Palisades, CA 90272

(Citizenship // U.S.A.)

Date:

Residence and Post Office Address:

Tewis commeester 827 Legering Avenue, Apt. #708 Los Angeles, California 90024 (Oitizenship: The Netherlands)

Serial No.: 08/878,474

## Section 1.56 Duty to Disclose Information Material to Patentability.

- (a) A patent by its very nature is affected with a public interest. The public interest is best served, and the most effective patent examination occurs when, at the time an application is being examined, the Office is aware of and evaluates the teachings of all information material to patentability. Each individual associated with the filing and prosecution of a patent application has a duty of candor and good faith in dealing with the Office, which includes a duty to disclose to the Office all information known to that individual to be material to patentability as defined in this section. The duty to disclose information exists with respect to each pending claim until the claim is cancelled or withdrawn from consideration becomes abandoned. Information material to the patentability of a claim that is cancelled or withdrawn from consideration need not be submitted if the information is not material to the patentability of any claim remaining under consideration in the application. There is no duty to submit information which is not material to the patentability of any existing claim. The duty to disclose all information known to be material to patentability is deemed to be satisfied if all information known to be material to patentability is deemed to be satisfied if all information known to be material to patentability is deemed to be satisfied if all information known to be material to patentability is deemed to be satisfied or submitted to the Office in the manner prescribed by §§ 1.97(b)-(d) and 1.98. However, no patent will be granted on an application in connection with which fraud on the Office was practiced or attempted or the duty of disclosure was violated through bad faith or intentional misconduct. The Office encourages applicants to carefully examine:
  - (1) prior art cited in search reports of a foreign patent office in a counterpart application, and
  - (2) the closest information over which individuals associated with the filing or prosecution of a patent application believe any pending claim patentably defines, to make sure that any material information contained therein is disclosed to the Office.
- (b) Under this section, information is material to patentability when it is not cumulative to information already of record or being made of record in the application, and
  - (1) It establishes, by itself or in combination with other information, a prima facie case of unpatentability of a claim; or
    - (2) It refutes, or is inconsistent with, a position the applicant takes in:
      - (i) Opposing an argument of unpatentability relied on by the Office, or
      - (ii) Asserting an argument of patentability.

A prima facie case of unpatentability is established when the information compals a conclusion that a claim is unpatentable under the preponderance of evidence, burden-of-proof standard, giving each term in the claim its broadest reasonable construction consistent with the specification, and before any consideration is given to evidence which may be submitted in an attempt to establish a contrary conclusion of patentability.

- (c) Individuals associated with the filing or prosecution of a patent application within the meaning of this section are:
  - (1) Each inventor named in the application;
  - (2) Each attorney or agent who prepares or prosecutes the application; and
  - (3) Every other person who is substantively involved in the preparation or prosecution of the application and who is associated with the inventor, with the assignce or with anyone to whom there is an obligation to assign the application.
- (d) Individuals other than the attorney, agent or inventor may comply with this section by disclosing information to the attorney, agent, or inventor.

Receipt is hereby acknowledged for the following the U.S. Patent and Trademark Office:

In re Patent of: De Robertis et al.

For: ENDODERM, CARDIAC AND NEURAL INDUCING FACTORS
Serial No.: 09/552,988

Filed: April 21, 2000
Docket: 510015-248

Date of Deposit: December 5, 2000

Due Date: \_N/A

☑ Transmittal sheet, in duplicate, containing Certificate of Mailing
 ☑ Revocation and Substitute Power of Attorney

CB/as

Receipt is hereby acknowledged for the following the U.S. Process and Trademark Office: In re Patent of: De Robertis et al.

For: ENDODERM. CARDIAC AND NEURAL INDUCING FACTORS
Serial No: 09/552,988
Filed: April 21, 2000
Docket: 510015-248

Dee Date: NA

Date of Deposit: December 5, 2000

Transmittal sheet, in duplicate, contain Revocation and Substitute Power of Ag 

## STATES PATENT AND TRADEMARK OFFICE

Patentee:

De Robertis et al.

Examiner

Not yet assigned

Serial No.

09/552,988

Art Unit

1646

Filed

April 21, 2000

Docket:

510015-248

Due Date:

n/a

Title:

ENDODERM, CARDIAC AND NEURAL INDUCING FACTORS

#### CERTIFICATE UNDER 37 CFR 1.8

I hereby certify that this correspondence and identified enclosures are being deposited with the United States Postal Service, first class mail, postage prepaid, under 37 C.F.R. 1.8 on the date indicated, and is addressed to the Commissioner for Patents, Washington, D.C. 20231 on December 5, 2000.

Commissioner for Patents Washington, D.C. 20231

Sir:

We are transmitting herewith the attached:

Transmittal Sheet in duplicate containing Certificate of Mailing

Revocation and Substitute Power of Attorney

Return postcard

Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers, if appropriate. Please charge any additional fees or credit overpayment to Deposit Account No. 16-2230. A duplicate of this sheet is enclosed.

OPPENHEIMER WOLFF & DONNELLY LLP 2029 Century Park East, 38th Floor Los Angeles, CA 90067-3024 (310) 788-5000

Name: Charles Berman Reg. No.: 29,249

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patentee:

De Robertis et al.

Examiner

Not yet assigned

Serial No.

09/552,988

**Art Unit** 

1646

Filed

April 21, 2000

Docket:

510015-248

Due Date:

n/a

Title:

ENDODERM, CARDIAC AND NEURAL INDUCING FACTORS

#### CERTIFICATE UNDER 37 CFR 1.8

I hereby certify that this correspondence and identified enclosures are being deposited with the United States Postal Service, first class mail, postage prepaid, under 37 C.F.R. 1.8 on the date indicated, and is addressed to the Commissioner for Patents, Washington, D.C. 20231 on <u>December 5, 2000.</u>

Amier Stewart

Commissioner for Patents Washington, D.C. 20231

Sir:

We are transmitting herewith the attached:

Transmittal Sheet in duplicate containing Certificate of Mailing

Revocation and Substitute Power of Attorney

Return postcard

Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers, if appropriate. Please charge any additional fees or credit overpayment to Peposis Account No. 16-2230. A duplicate of this sheet is enclosed.

OPPENHEIMER WOLFF & DONNELLY LLP 2029 Century Park East, 38th Floor Los Angeles, CA 90067-3024 (310) 788-5000

Name: Charles Berman Reg. No.: 29,249

**PATENT** 

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

De Robertis et al.

Examiner:

Unknown

Serial No.

09/552,988

Group Art Unit:

er Stewart

1646

Filed:

April 21, 2000

Docket No.

510015-248

Title:

ENDODERM, CARDIAC AND NEURAL INDUCING FACTORS

CERTIFICATE UNDER 37 C.F.R. 1.8: The undersigned hereby certifies that this paper and its enclosures are being deposited in the United States Postal Service, as first class mail, with sufficient postage, in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on

REVOCATION AND SUBSTITUTE POWER OF ATTORNEY

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

In the matter of the above-identified application, I hereby revoke all power of attorney heretofore given and hereby appoint:

Charles Berman, Reg. 29,249 Louis J. Bovasso, Reg. 24,075 Marc E. Brown, Reg. 28,590 Christopher Darrow, Reg. 30,166 Michael B. Farber, Reg. 32,612 Scott R. Hansen, Reg. 38,486 Michael D. Harris, Reg. 26,690 Douglas N. Larson, Reg. 29,401 Spyros J. Lazaris, Reg. 45,981 Sung Oh, Reg. P45,583 David J. Oldenkamp, Reg. 29,421 William Poms, Reg. 18,782 Alan C. Rose, Reg. 17,047 Charles Rosenberg, Reg. 31,464 Guy P. Smith, Reg. 20,142 Ronald S. Tamura, Reg. 43,179 Gregory B. Wood, Reg. 28,133 Daniel Chapik, Reg. 43,424 Harold D. Jastram, Reg. 19,777 Alan D. Kamrath, Reg. 28,227 Chad Klingbeil, Reg. 33,002 Craig J. Lervick, Reg. 35,244 Cyrus Morton, Reg. 44,954 Bruce Canter, Reg. 34,792 Louis C. Cullman, Reg. 39,645 Monique Heyninck, Reg. P44,763 James W. Inskeep, Reg. 33,910 Kurt A. MacLean, Reg. 31,118
Ben H. Bedi, Reg. 39,904
Everitt George Beers, Reg. 40,508
Michael K. Bosworth, Reg. 28,186
Justin F. Boyce, Reg. 40,920
Chris W. Chou, Reg. 41,672
Anthony B. Diepenbrock III, Reg. 39,960
Robert O. Guillot, Reg. 28,852
—Claude A.S. Hamrick, Reg. 22,586
Esther La, Reg. 43,734
Leah Sherry, Reg. 43,918
Marc Bobys, Reg. 45,267

whose address is:

## OPPENHEIMER WOLFF & DONNELLY LLP

2029 Century Park East, 38th Floor Los Angeles, California 90067-3024 Telephone (310) 788-5000 Telefax (310) 788-5100 Attention: Krista Vink Venegas

to represent the undersigned before the United States Patent and Trademark Office and to make or receive payments on behalf of the undersigned. Please direct all future correspondence and telephone calls to:

## OPPENHEIMER WOLFF & DONNELLY LLP

2029 Century Park East, 38th Floor Los Angeles, California 90067-3024 Telephone (310) 788-5000 Telefax (310) 788-5100 Attention: Krista Vink Venegas

Name: Linda S. Stevenson

Manager, Patent Prosecution



UNITED STATÉS DEPARTMENT OF COMMERCE Patent and Trademark Office ASSISTANT SECRETARY AND COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

APRIL 10, 2001

PTAS

OPPENHEIMER WOLFF & DONNELLY LLP CHARLES BERMAN 2029 CENTURY PARK EAST, 38TH FLOOR LOS ANGELES, CA 90067-3024



\*101601052A\*

UNITED STATES PATENT AND TRADEMARK OFFICE NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 703-308-9723. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, ASSIGNMENT DIVISION, BOX ASSIGNMENTS, CG-4, 1213 JEFFERSON DAVIS HWY, SUITE 320, WASHINGTON, D.C. 20231.

RECORDATION DATE: 01/22/2001

REEL/FRAME: 011469/0424

NUMBER OF PAGES: 2

BRIEF: ASSIGNMENT OF ASSIGNOR'S INTEREST (SEE DOCUMENT FOR DETAILS).

ASSIGNOR:

DEROBERTIS, EDWARD M.

DOC DATE: 12/07/2000

ASSIGNOR:

BOUWMEESTER, TEWIS

DOC DATE: 12/08/2000

ASSIGNEE:

REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE 1111 FRANKLIN STREET, 5TH FLOOR

OAKLAND, CALIFORNIA 94607-5200

SERIAL NUMBER: 09552988

PATENT NUMBER:

FILING DATE: 04/21/2000

ISSUE DATE:

DOCKETED

PAULA MCCRAY, EXAMINER ASSIGNMENT DIVISION OFFICE OF PUBLIC RECORDS

APR 1 & 2001

OWD-LA

RECEIVED

APR 17 2001

OWD

O1-31-2001

EET

U.S. DEPARTMENT OF COMMERCE Patent and Trademark Office

FORM PTO-1595 (Rev. 6-93) OMB No. 0651-0011 (exp. 4/94) Docket No. - 30962.2-US-U1

tached original documents or copy thereof.  2. Name and address of receiving party(ies):
The Regents of the University of California
1111 Franklin Street, 5th Floor Oakland, California 94607-5200
Cariand, Camorna 94007-3200
The second of the second secon
The second secon
Additional name(s) & address(as) attached?
BECEIVEIN
JAN 2 2 2001    //
execution date of the application is:
The Property AND
B. Patent No.(s)
d? ☐ Yes ⊠ No
6. Total number of applications and patents involved: 1
7. Total fee (37 CFR 3.41): \$40.00
Authorized to be charged to deposit account
8. Please charge any additional fees or credit any
overpayments to our Deposit account number: 16-2230
IS SPACE
$\wedge$
is true and correct and any attached copy is a true copy of the
(
1 650
January 17, 2001
nature Date
Total number of pages including cover sheet, attachments, and docume
pertion
perovu
and Trademarks
and Trademarks
leads C. 20231 Deminutes ner document to be recorded, including time for reviewing the
tents  2. 20231  3. minutes per document to be recorded, including time for reviewing the cover sheet. Send comments regarding this burden estimate to the U.S.
leads C. 20231 Deminutes ner document to be recorded, including time for reviewing the
tents  2. 20231  3. minutes per document to be recorded, including time for reviewing the cover sheet. Send comments regarding this burden estimate to the U.S.
tents  2. 20231  3. minutes per document to be recorded, including time for reviewing the cover sheet. Send comments regarding this burden estimate to the U.S.
tents  2. 20231  3. minutes per document to be recorded, including time for reviewing the cover sheet. Send comments regarding this burden estimate to the U.S.
tents  2. 20231  3. minutes per document to be recorded, including time for reviewing the cover sheet. Send comments regarding this burden estimate to the U.S.

Attorney Docket No. 510015-248

#### ASSIGNMENT

U.C. Case No. 2001-054-1

For good and valuable consideration, the receipt of which is hereby acknowledged, ASSIGNOR(S),

1. Edward M. DeRobertis

2. Tewis Bouwnesser

hereby sells, assigns and transfers to ASSIGNEE, The Regents of the University of California, a California Corporation, having its statewide administrative offices located at 1111 Franklin Street, 5th Floor, Oakland, CA 94607-5200, and the successors, essigns and legal representatives of the ASSIGNEE all of its right, title and interest for the United States and its territorial possessions and in all foreign countries in and to, any and all improvements which are disclosed in the invention entitled:

ENDO	DERM, CARDIAC AND NEURA	L INDUCING FACTO	rs —
and w	hich is found in		
(a)	U.S. provisional application filed herewith and listing the above named persons as inventors		
(ъ) _	U.S. patent application filed herewith and listing the above names persons as inventors		
(c)	U.S. application scrial no. 09/552.988, filed on April 21, 2000		
(q)	U.S. Patent No.:	issued	
extensi Letters ASSIC	ion, conversion to 35 USC 111(a) of Patent and all rights under all Inter	er substitute thereof, and mational Conventions i o assignment, sale, agre	or any continuation, division, continuation-in-part, any reissue, rectamination or extension of said for the Protection of Industrial Property; ement or encumbrance has been or will be made or
nets at a coession of wind wind wind wind wind wind with the coession of the c	nd documents relating to said investible to ASSIGNOR and will testify ill promptly execute and deliver to a rits required to apply for, obtain, mut and said equivalents thereof which by of record is authorized and requestate and serial number of said appliance and serial number of said appliance.	rtion and said Letters Prices to the same in any it ASSIGNEE or its legal aimain, issue or enforce may be necessary or desired by the execution of ication when officially a	
AND d Jaited	he <u>ASSIGNOR(S)</u> requests the Cor States an any reissue or extension	ministioner of Patents a thereof to the ASSIGN	nd Trademarks to issue said Letters Patent of the EE, The Regents of the University of California.
	ed this		Edward M. Daksbertis
	ed this		Signature of Inventor(a)

LA: 265639 +01 12/07/2000

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patentee:

De Robertis et al.

Examiner

Not yet assigned

Serial No.

09/552,988

Art Unit

1646

Filed

April 21, 2000

Docket:

510015-248

Due Date:

n/a

Title:

ENDODERM, CARDIAC AND NEURAL INDUCING FACTORS

#### CERTIFICATE UNDER 37 CFR 1.8

I hereby certify that this correspondence and identified enclosures are being deposited with the United States Postal Service, first class mail, postage prepaid, under 37 C.F.R. 1.8 on the date indicated, and is addressed to Box: Assignments, Commissioner for Patents, Washington, D.C. 20231 on January 17, 2001.

Amber Steway

Box: Assignments

Commissioner for Patents Washington, D.C. 20231

Sir:

We are transmitting herewith the attached:

▼ Transmittal Sheet in duplicate containing Certificate of Mailing

Assignment of the invention to The Regents of the University of California and Recordation Form Cover Sheet

Check in the amount of \$40.00 to cover assignment recordation fee

Return postcard

Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers, if appropriate. Please charge any additional fees or credit overpayment to Deposit Account No. 16-2230. A duplicate of this sheet is enclosed.

OPPENHEIMER WOLFF & DONNELLY LLP 2029 Century Park East, 38th Floor Los Angeles, CA 90067-3024 (310) 788-5000

Name: Charles Berman

Reg. No.: 29,249